Vaxart Inc VXRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VXRT is a good fit for your portfolio.
News
-
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
-
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
-
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
-
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $0.71
- Day Range
- $0.69–0.72
- 52-Week Range
- $0.56–1.59
- Bid/Ask
- $0.70 / $0.71
- Market Cap
- $104.19 Mil
- Volume/Avg
- 12 / 684,461
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 125.63
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 164
- Website
- https://www.vaxart.com
Valuation
|
Metric
|
VXRT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.46 |
Price/Sales | 125.63 |
Price/Cash Flow | — |
Price/Earnings
VXRT
Financial Strength
|
Metric
|
VXRT
|
|---|---|
Quick Ratio | 4.67 |
Current Ratio | 5.07 |
Interest Coverage | −101.90 |
Quick Ratio
VXRT
Profitability
|
Metric
|
VXRT
|
|---|---|
Return on Assets (Normalized) | −54.37% |
Return on Equity (Normalized) | −77.97% |
Return on Invested Capital (Normalized) | −64.96% |
Return on Assets
VXRT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tvrmw | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nnhskkb | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mpnvfb | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Jqxhy | $40.7 Bil | |
MRNA
| Moderna Inc | Scjm | $30.7 Bil | |
ARGX
| argenx SE ADR | Tjphl | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Pzzd | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zygztl | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mmdvq | $17.7 Bil | |
INCY
| Incyte Corp | Krscs | $12.4 Bil |